Volver a la clasificación

BGM Group Ltd. (BGM)

Sobrevalorada
HealthcareDrug Manufacturers - Specialty & GenericChina

Fundamental

32

Precio

$7.42

Capitalización Bursátil

$100M

Parte 1 · Cuánto vale la empresa

Resumen

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a antitussive and expectorant medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers. BGM Group Ltd. is based in Chengdu, China.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Generated on 18 de septiembre de 2026 with claude-haiku-4-5 — shared with all users

Jinhe Biotechnology Co., Ltd. (金河生物科技股份有限公司)002688.SZ

Both are Chinese producers of tetracycline-class antibiotic active ingredients and premixes sold to the same livestock, poultry and feed customers at home and for export.

Ningxia Tairui Pharmaceutical Co., Ltd. (宁夏泰瑞制药股份有限公司)Not tracked

A non-listed Chinese maker of non-sterile veterinary antibiotic active ingredients and feed additives, selling into the same animal-health raw-material market as BGM's oxytetracycline business.

Wuhan Hvsen Biotechnology Co., Ltd. (武汉回盛生物科技股份有限公司)300871.SZ

Makes veterinary antibiotic active ingredients and the finished animal medicines built on them, competing for the large Chinese pig, poultry and aquaculture producers that also buy BGM's products.

China Animal Husbandry Industry Co., Ltd. (中牧实业股份有限公司)600195.SS

A long-established state-backed supplier of veterinary drugs and veterinary active ingredients to Chinese farms, overlapping with BGM on the animal-medicine side of its pharmaceutical segment.

Balance y Liquidez

Ingresos

$39M

Últimos 12 meses hasta el último trimestre publicado — estimación a partir de métricas por acción

Beneficio Neto

$-25M

Últimos 12 meses hasta el último trimestre publicado — estimación a partir de métricas por acción

Flujo de Caja Libre

$-5M

Patrimonio Neto Total

$391M

Pasivo Total

$42M

Ratio de Liquidez

1.24

Cobertura de Intereses

-

Deuda/EBITDA

-

Beneficio Por Acción

Ingresos y Beneficio Neto

Flujo de Caja Libre

Desglose de Ingresos

Estado histórico

Márgenes en el tiempo

La deuda en el tiempo

Cuánto pesa la deuda

Cuadro de crecimiento

Crecimiento — Ingresos

Estimación de Valor Justo

Caso generalSobrevalorado

Valor Justo

$0.49

Precio Actual

$7.42

Margen de Seguridad

-1414.5%

Rango de Valor Justo

$0.47 - $0.52

Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.

Métodos de Estimación

Precio objetivo de los analistas:Datos insuficientes para calcularlo
Flujo de caja descontado (DCF):$0.49
Múltiplo sobre beneficios (P/E):Datos insuficientes para calcularlo
Fórmula de crecimiento de Graham:Datos insuficientes para calcularlo
Valor de la capacidad de generar beneficios (EPV):Datos insuficientes para calcularlo
P/B justificado:Datos insuficientes para calcularlo
Descuento de dividendos (Gordon):Datos insuficientes para calcularlo
P/FFO, fondos de operaciones:Datos insuficientes para calcularlo
Beneficios de mitad de ciclo:Datos insuficientes para calcularlo
Múltiplo sobre ingresos:$0.77

Métricas de Valoración

Ratio P/E

-

ROE

-5.1%

Ratio P/B

0.13

P/FCF

-

Margen Bruto

16.6%

ROIC

-2.5%

Radar de Rentabilidad

Creación de Valor (Ventaja Competitiva)

ROIC

-2.5%

WACC

15.0%

ROIC − WACC

-17.5 pp

El ROIC está por debajo del coste del capital: la empresa destruye valor por cada dólar invertido.

Criterios de Análisis Fundamental

Superado (4)

  • P/B Ratio 0.13
  • Debt/Equity ratio
  • Current Ratio
  • DCF valuation (Undervalued)

Fallido (11)

  • EPS shows upward trend
  • Price CAGR -54.62%
  • ROIC -2.5%
  • Gross Margin 16.6%
  • Operating Margin -33.2%
  • Positive Free Cash Flow
  • ROE -7.0%
  • Revenue Growth 5Y -5.4%
  • Share Dilution 1435.7%
  • Net Margin Trend -52.6% vs -5.7%
  • Piotroski F-Score 3/9

No disponible (12)

  • P/FCF NaN
  • Dividend Payout NaN%
  • CapEx intensity
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • Analyst Consensus (Finnhub)
  • Earnings Surprise (Finnhub)
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)

Piotroski F-Score

3/9

Preocupaciones financieras graves

score
criteria

Calidad de los Beneficios

-

Baja calidad: investigue la contabilidad

Dilución de Acciones

1435.7%

Emitiendo nuevas acciones, diluyendo la participación

Participaciones institucionales

No hay declaraciones institucionales para esta empresa.

Gobernanza

Equipo Directivo

NombreCargoEdad
Ms. Huandi ZhaoCo-Chief Executive Officer & Director40
Ms. Li HongCo-Chief Executive Officer-
Ms. Yaxuan ZhaiChief Financial Officer30

Parte 2 · El precio y el momento de entrar

Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.

Latest News

Recent headlines for BGM, sourced from Markets Gazette.

No recent news for BGM.